contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


asarina-pharma-ab-publ-releases-year-end-report-2022

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Asarina Pharma

(Stockholm, 27 February 2023.) Asarina Pharma today announces that it has released its Year End Report 2022. In the second half of 2022 the company continued its Phase IIa study in Sepranolone...

<div class="abstract">(Stockholm, 27 February 2023.) Asarina Pharma today announces that it has released its Year End Report 2022. In the second half of 2022 the company continued its Phase IIa study in Sepranolone for Tourette Syndrome, on schedule, completing Last Patient Last Visit on February 1, less than 12 months after commencement. The patient dropout rate remained unexpectedly low throughout the study. Results continue to be expected at the end of March 2023.</div>FINANCIAL HIGHLIGHTS<ul><li>Operating costs (MSEK 6.7) well under control&nbsp;</li><li>Cash reserves at year-end (MSEK 13.6) enough to finance completion of Tourette study&nbsp;</li><li>Strong balance sheet due to conversion of loan in May 2022</li></ul>R&amp;D HIGHLIGHTSRecruitment completed: patient recruitment to Phase IIa study in Tourette completed in October 2022. A total of 28 patients were enrolled. The last patient was randomized on October 14.Extensive preclinical study published: on 6 October Asarina Pharma announced the publication of a comprehensive new preclinical study in the Neurobiology of Stress, the fourth in a series of four. Results increase the Translatability of Asarina Pharma's data and provide further evidence for pursuing further clinical tests and an initial clinical trial in OCD.Last Patient Last Visit: On February 1, 2023, following the reporting period, Last Patient Last Visit was reported in our Phase IIa Tourette study. The dropout rate remained unexpectedly low (two of the 28 patients dropped out.)Topline results for the Study remain expected to be released at the end of March 2023.CEO STATEMENTCEO Peter Nordkild:&nbsp;"An overview of developments in the Tourette market and competitor landscape in 2022 confirms two major trends - its growing prevalence, backed up by a substantial US CDC Report - and the continuing unmet need for safer treatments. These are still early days for Sepranolone in Tourette. Nevertheless, we are keenly aware of just how unique its safety profile is, and how much that could set Sepranolone apart in a market such as Tourette. We look forward to releasing our topline results and further exploring the data."Read the full CEO Statement here: <a href="https://asarinapharma.com/investors/financial-reports/">https://asarinapharma.com/investors/financial-reports/</a>